These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 25427622

  • 1. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P, Remuzzi G, Ruggenenti P.
    Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
    [Abstract] [Full Text] [Related]

  • 2. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K.
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
    Cravedi P, Sghirlanzoni MC, Marasà M, Salerno A, Remuzzi G, Ruggenenti P.
    Am J Nephrol; 2011 Apr; 33(5):461-8. PubMed ID: 21508634
    [Abstract] [Full Text] [Related]

  • 4. An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
    Maas R, Hofstra JM, Wetzels JF.
    Minerva Med; 2012 Aug; 103(4):253-66. PubMed ID: 22805618
    [Abstract] [Full Text] [Related]

  • 5. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA, Trillini M, Portalupi V, Gennarini A, Tomatis F, Villa A, Perna A, Rubis N, Remuzzi G, Ruggenenti P.
    Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
    [Abstract] [Full Text] [Related]

  • 6. Latest treatment strategies for membranous nephropathy.
    Ruggenenti P, Cravedi P, Remuzzi G.
    Expert Opin Pharmacother; 2007 Dec; 8(18):3159-71. PubMed ID: 18035960
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
    Busch M, Gerth J, Ott U, Schip A, Haufe CC, Gröne HJ, Wolf G.
    Med Klin (Munich); 2008 Jul 15; 103(7):519-24. PubMed ID: 18604487
    [Abstract] [Full Text] [Related]

  • 8. Treatment of idiopathic membranous nephropathy.
    Hofstra JM, Fervenza FC, Wetzels JF.
    Nat Rev Nephrol; 2013 Aug 15; 9(8):443-58. PubMed ID: 23820815
    [Abstract] [Full Text] [Related]

  • 9. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
    Scolari F, Dallera N, Gesualdo L, Santoro D, Pani A, Santostefano M, Feriozzi S, Mani LY, Boscutti G, Messa P, Magistroni R, Quaglia M, Ponticelli C, Ravani P.
    BMJ Open; 2019 Dec 04; 9(12):e029232. PubMed ID: 31806605
    [Abstract] [Full Text] [Related]

  • 10. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
    Cravedi P.
    G Ital Nefrol; 2012 Dec 04; 29(3):274-82; discussion 292. PubMed ID: 22718450
    [Abstract] [Full Text] [Related]

  • 11. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.
    Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G.
    Clin J Am Soc Nephrol; 2007 Sep 04; 2(5):932-7. PubMed ID: 17702725
    [Abstract] [Full Text] [Related]

  • 12. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
    Anjum N, Nabi Z, Alam MA.
    J Ayub Med Coll Abbottabad; 2019 Sep 04; 31(2):265-268. PubMed ID: 31094128
    [Abstract] [Full Text] [Related]

  • 13. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R, Laliberte K, Huizenga NR, Rosenthal JK, Jeyabalan A, Collins AB, Cortazar FB, Niles JL.
    Am J Kidney Dis; 2021 Dec 04; 78(6):793-803. PubMed ID: 34174365
    [Abstract] [Full Text] [Related]

  • 14. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy.
    Busch M, Rüster C, Schinköthe C, Gerth J, Wolf G.
    Clin Nephrol; 2013 Aug 04; 80(2):105-13. PubMed ID: 23587125
    [Abstract] [Full Text] [Related]

  • 15. Overview of current and alternative therapies for idiopathic membranous nephropathy.
    Tran TH, J Hughes G, Greenfeld C, Pham JT.
    Pharmacotherapy; 2015 Apr 04; 35(4):396-411. PubMed ID: 25884528
    [Abstract] [Full Text] [Related]

  • 16. Treatment of membranous nephropathy: time for a paradigm shift.
    Ruggenenti P, Fervenza FC, Remuzzi G.
    Nat Rev Nephrol; 2017 Sep 04; 13(9):563-579. PubMed ID: 28669992
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
    Ou JY, Chen YW, Li TL, Shan HZ, Cui S, Lai JJ, Xiao Y.
    Nephrol Ther; 2022 Apr 04; 18(2):104-112. PubMed ID: 35074299
    [Abstract] [Full Text] [Related]

  • 18. B cell suppression in primary glomerular disease.
    Rood IM, Hofstra JM, Deegens JK, Wetzels JF.
    Adv Chronic Kidney Dis; 2014 Mar 04; 21(2):166-81. PubMed ID: 24602466
    [Abstract] [Full Text] [Related]

  • 19. Membranous Nephropathy: Core Curriculum 2021.
    Alsharhan L, Beck LH.
    Am J Kidney Dis; 2021 Mar 04; 77(3):440-453. PubMed ID: 33487481
    [Abstract] [Full Text] [Related]

  • 20. [Membranous glomerulonephritis: better therapy with autoantibody monitoring?].
    Stahl RA, Hoxha E, Helmchen U.
    Dtsch Med Wochenschr; 2011 Aug 04; 136(34-35):1733-7. PubMed ID: 21877306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.